PMC:7445716 / 55668-56225 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T411","span":{"begin":30,"end":34},"obj":"Body_part"},{"id":"T412","span":{"begin":182,"end":193},"obj":"Body_part"},{"id":"T413","span":{"begin":215,"end":218},"obj":"Body_part"},{"id":"T414","span":{"begin":297,"end":304},"obj":"Body_part"},{"id":"T415","span":{"begin":317,"end":327},"obj":"Body_part"},{"id":"T416","span":{"begin":331,"end":335},"obj":"Body_part"}],"attributes":[{"id":"A411","pred":"fma_id","subj":"T411","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A412","pred":"fma_id","subj":"T412","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A413","pred":"fma_id","subj":"T413","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A414","pred":"fma_id","subj":"T414","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A415","pred":"fma_id","subj":"T415","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A416","pred":"fma_id","subj":"T416","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T539","span":{"begin":260,"end":280},"obj":"Disease"},{"id":"T540","span":{"begin":350,"end":358},"obj":"Disease"},{"id":"T541","span":{"begin":379,"end":383},"obj":"Disease"}],"attributes":[{"id":"A539","pred":"mondo_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A541","pred":"mondo_id","subj":"T541","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T445","span":{"begin":40,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T446","span":{"begin":55,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T447","span":{"begin":75,"end":77},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T448","span":{"begin":90,"end":92},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T449","span":{"begin":98,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T450","span":{"begin":109,"end":111},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T451","span":{"begin":125,"end":127},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T452","span":{"begin":145,"end":147},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T453","span":{"begin":161,"end":163},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T454","span":{"begin":250,"end":255},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T455","span":{"begin":306,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T456","span":{"begin":317,"end":327},"obj":"http://purl.obolibrary.org/obo/CL_0000738"},{"id":"T457","span":{"begin":329,"end":335},"obj":"http://purl.obolibrary.org/obo/CLO_0001757"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T66393","span":{"begin":30,"end":32},"obj":"Chemical"},{"id":"T35461","span":{"begin":63,"end":65},"obj":"Chemical"},{"id":"T95050","span":{"begin":98,"end":100},"obj":"Chemical"},{"id":"T8180","span":{"begin":182,"end":193},"obj":"Chemical"},{"id":"T86158","span":{"begin":297,"end":304},"obj":"Chemical"},{"id":"T45814","span":{"begin":384,"end":386},"obj":"Chemical"},{"id":"T60573","span":{"begin":435,"end":446},"obj":"Chemical"},{"id":"T68008","span":{"begin":448,"end":457},"obj":"Chemical"},{"id":"T60198","span":{"begin":459,"end":477},"obj":"Chemical"},{"id":"T26901","span":{"begin":482,"end":493},"obj":"Chemical"}],"attributes":[{"id":"A26684","pred":"chebi_id","subj":"T66393","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A49114","pred":"chebi_id","subj":"T66393","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A56606","pred":"chebi_id","subj":"T35461","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A50900","pred":"chebi_id","subj":"T35461","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A9941","pred":"chebi_id","subj":"T95050","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A10810","pred":"chebi_id","subj":"T95050","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A64821","pred":"chebi_id","subj":"T8180","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A67418","pred":"chebi_id","subj":"T86158","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A12230","pred":"chebi_id","subj":"T45814","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A54282","pred":"chebi_id","subj":"T60573","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A8364","pred":"chebi_id","subj":"T68008","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A2703","pred":"chebi_id","subj":"T60198","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A13577","pred":"chebi_id","subj":"T26901","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PubTator","denotations":[{"id":"674","span":{"begin":62,"end":66},"obj":"Gene"},{"id":"675","span":{"begin":97,"end":101},"obj":"Gene"},{"id":"676","span":{"begin":132,"end":137},"obj":"Gene"},{"id":"702","span":{"begin":29,"end":33},"obj":"Gene"},{"id":"768","span":{"begin":349,"end":359},"obj":"Species"},{"id":"923","span":{"begin":259,"end":279},"obj":"Disease"},{"id":"924","span":{"begin":364,"end":382},"obj":"Disease"}],"attributes":[{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"Gene:3569"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"Gene:3576"},{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"Gene:7124"},{"id":"A702","pred":"tao:has_database_id","subj":"702","obj":"Gene:3552"},{"id":"A768","pred":"tao:has_database_id","subj":"768","obj":"Tax:2697049"},{"id":"A923","pred":"tao:has_database_id","subj":"923","obj":"MESH:D001327"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-sentences","denotations":[{"id":"T310","span":{"begin":0,"end":35},"obj":"Sentence"},{"id":"T311","span":{"begin":36,"end":68},"obj":"Sentence"},{"id":"T312","span":{"begin":69,"end":103},"obj":"Sentence"},{"id":"T313","span":{"begin":104,"end":139},"obj":"Sentence"},{"id":"T314","span":{"begin":140,"end":328},"obj":"Sentence"},{"id":"T315","span":{"begin":329,"end":378},"obj":"Sentence"},{"id":"T316","span":{"begin":379,"end":557},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T695","span":{"begin":260,"end":280},"obj":"Phenotype"},{"id":"T696","span":{"begin":365,"end":378},"obj":"Phenotype"}],"attributes":[{"id":"A695","pred":"hp_id","subj":"T695","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A696","pred":"hp_id","subj":"T696","obj":"http://purl.obolibrary.org/obo/HP_0011096"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T689","span":{"begin":63,"end":67},"obj":"PR:000001393"},{"id":"T690","span":{"begin":98,"end":102},"obj":"PR:000001395"},{"id":"T691","span":{"begin":133,"end":138},"obj":"PR:000000134"},{"id":"T692","span":{"begin":182,"end":193},"obj":"CHEBI:5386;CHEBI:5386"},{"id":"T693","span":{"begin":194,"end":204},"obj":"GO:0042571"},{"id":"T694","span":{"begin":220,"end":223},"obj":"NCBITaxon:10376"},{"id":"T695","span":{"begin":260,"end":270},"obj":"UBERON:0002405"},{"id":"T696","span":{"begin":317,"end":327},"obj":"CL:0000738"},{"id":"T697","span":{"begin":350,"end":360},"obj":"SP_7"},{"id":"T698","span":{"begin":415,"end":433},"obj":"CHEBI:5801;CHEBI:5801;DG_20"},{"id":"T699","span":{"begin":435,"end":446},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T700","span":{"begin":448,"end":457},"obj":"CHEBI:367163;CHEBI:367163;DG_13"},{"id":"T701","span":{"begin":459,"end":477},"obj":"CHEBI:12071;CHEBI:12071;DG_36"},{"id":"T702","span":{"begin":482,"end":493},"obj":"DG_35"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"2_test","denotations":[{"id":"32840686-32662899-63205780","span":{"begin":18,"end":20},"obj":"32662899"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.2 pg/ml (\u003c 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8–6.4 pg/ml), IL-8: 20.0 pg/ml (6.7–16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Increased total protein (52 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Demyelinating\nAIDP NA IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilation Improvement of motor symptoms"}